Skip to main content

Microsoft to Acquire Rosetta Biosoftware from Merck

NEW YORK (GenomeWeb News) – Microsoft has signed an agreement to acquire Rosetta Biosoftware, a unit of Rosetta Inpharmatics, from parent company Merck for undisclosed consideration.

Microsoft said that the deal will enable it to add genetic, genomic, metabolomic, and proteomic data management software into its own Amalga Life Sciences platform for "enhanced translational research capabilities."

Merck will become a customer of the Amalga Life Sciences 2009 platform and provide "strategic input" to Microsoft on the evolution of new solutions that incorporate Rosetta Biosoftware technologies, Microsoft said. The Redmond, Wash.-based software giant launched the Amalga Life Sciences 2009 platform in April.

"The newly combined offering will enable customers to improve the management and analysis of genomic, biological and research data, helping to bring lifesaving drugs and therapies to market faster and accelerate the realization of personalized medicine," Peter Neupert, corporate vice president of the Health Solutions Group at Microsoft, said in a statement.

The firms expect to close the deal at the end of June. Microsoft anticipates the new Amalga platform incorporating the Rosetta Biosoftware technologies to be available early next year. It also said that it is "pursuing hiring Rosetta Biosoftware employees who can fill roles that are critical to the effective incorporation of Rosetta Biosoftware technologies into the Amalga Life Sciences platform."

Until the acquisition is finalized, Rosetta Biosoftware will continue to operate as a unit of Rosetta Inpharmatics.

Filed under

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.